Mexico and Brazil do not plan to restrict access to AstraZeneca’s COVID-19 vaccine after Britain’s drug control agency recommended it amid the potential risk of blood clots.
The statement comes after the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA). recommend This vaccine is only for use in people 30 years and older, as it may be linked to a rare blood clot.
The agency said it examined 79 reports of rare thrombosis after vaccination, with 19 deaths, eleven out of 19 who died under the age of 50, while three were under age. 30 years
Cofepris, Mexico̵7;s drug regulator, said it was still reviewing recommendations. However, it does not plan to limit the use of AstraZeneca vaccine for any age group or group, ”Reuters. reportSo far, Mexico has received 3.5 million doses of the vaccine.
Meanwhile, Brazilian health regulator Anvisa said the vaccine’s benefits outweigh its risks and recommend its continued use. The news agency noted that Brazil had given more than 4 million shots to date and that only 47 coagulation events were registered.
The UK’s advice comes the same day the European Medicines Agency (EMA) Safety Commission concluded:Possible links”Between a rare blood clot and a vaccine there is
Concerns about blood clots in a small number of patients led more than ten countries to block the use of the vaccine last month. Oxford University Pause clinical trials The vaccine was tested in 300 children ages 6 to 17 while awaiting the MHRA’s opinion on the coagulation report.
AstraZeneca confirmed that the evidence found no link between the vaccine and coagulation.